Molecular Analysis and Treatment Options of Thymic Malignancies

Sponsor

Shanghai Chest Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT05667948

Collaborator

(none)

500

Enrollment

Location

132

Anticipated Duration (Months)

3.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies.

In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.

Condition or Disease	Intervention/Treatment	Phase
Thymic Epithelial Tumor Thymic Carcinoma Thymic Cancer	Drug: Chemotherapy

Study Design

Study Type:

Observational

Anticipated Enrollment :

500 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors

Actual Study Start Date :

Jan 1, 2016

Anticipated Primary Completion Date :

Dec 31, 2025

Anticipated Study Completion Date :

Dec 31, 2026

Outcome Measures

Primary Outcome Measures

Objective response rate (ORR) [20 years]
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Disease control rate (DCR) [20 years]
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Progression-free survival (PFS) [20 years]
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Secondary Outcome Measures

Overall survival (OS) [20 years]
Collect detailed clinical information on patients with thymic malignancies via the electronic medical records

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically proven diagnosis of thymic malignancies
18 years of age or older
Ability to understand and the willingness to sign a written informed consent document